任长老的个人主页 - 老虎社区

任长老

任长老

暂无个人介绍

IP属地：山东

22关注

2粉丝

1主题

0勋章

2021-02-04

绝对的龙头

Tilray® Exports First Shipment of Medical Cannabis to Spain

2021-01-12

$Tilray Inc.(TLRY)$如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3560331351209354","uuid":"3560331351209354","gmtCreate":1597237328485,"gmtModify":1611931383023,"name":"任长老","pinyin":"rclrenchanglao","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b5b555697d10a84da2515eebe013f79a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":22,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"山东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":317626583,"gmtCreate":1612446954342,"gmtModify":1703762000043,"author":{"id":"3560331351209354","authorId":"3560331351209354","name":"任长老","avatar":"https://static.tigerbbs.com/b5b555697d10a84da2515eebe013f79a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560331351209354","authorIdStr":"3560331351209354"},"themes":[],"htmlText":"绝对的龙头","listText":"绝对的龙头","text":"绝对的龙头","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/317626583","repostId":"2108711273","repostType":2,"repost":{"id":"2108711273","pubTimestamp":1612436400,"share":"https://www.laohu8.com/m/news/2108711273?lang=&edition=full","pubTime":"2021-02-04 19:00","market":"us","language":"en","title":"Tilray® Exports First Shipment of Medical Cannabis to Spain","url":"https://stock-news.laohu8.com/highlight/detail?id=2108711273","media":"Business Wire","summary":"Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain wi","content":"<html><body><p><b><i>Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis</i></b></p>\n<p><b><i>Tilray medical cannabis will now be available in 17 countries around the world</i></b></p>\n<p>Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech (\"Worldpharma\"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (\"Tilray Portugal\"), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17<sup>th</sup> country to receive Tilray medical cannabis worldwide.</p>\n<p>The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain. With Tilray's pharmaceutical-grade cannabis, Worldpharma will develop medical cannabis products for clinical trials in Spanish Hospitals for diseases such as Alzheimer's, Parkinson’s disease, and skin inflammation.</p>\n<p>Brendan Kennedy, Tilray’s Chief Executive Officer, said, \"We’re incredibly honored to be the first cannabis company to be approved and to ship medical cannabis into Spain. As we continue to work with regulators around the world, we are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.\"</p>\n<p>Juan Jose Garcia Miquel, Founder of World Pharma Biotech, said, \"We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP certified products that meet the highest of E.U. and Spanish Pharmacology Standards. We intend to work with the companies with the highest quality pharmaceutical standards to give doctors and patients total confidence. It's been impossible to reach this level of quality from other cannabis authorized companies in Spain.\"</p>\n<p>Sascha Mielcarek, Tilray’s General Manager for Europe, said, \"We are very pleased to partner with Worldpharma. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need, paving the way for future medical cannabis standards of care.\"</p>\n<p>Tilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.</p>\n<p>Tilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.</p>\n<p><b>About Tilray®</b></p>\n<p>Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.</p>\n<p><b>About WorldPharma Biotech</b></p>\n<p>World Pharma Biotech was founded in 2014 in Valencia, Spain, focused on vegetal ingredients for nutraceuticals, cosmetics, and pharmaceutical industries. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and Start-up companies from Valencia University. The extraction and purification lab's primary focus is the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains \"forward-looking statements\" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and \"forward-looking information\" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, \"may\", \"would\", \"could\", \"will\", \"likely\", \"expect\", \"anticipate\", \"believe, \"intend\", \"plan\", \"forecast\", \"project\", \"estimate\", \"outlook\" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading \"Risk Factors\" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210204005187/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>For further information: </b><br/>Tilray Global:<br/>Berrin Noorata<br/>news@tilray.com</p>\n<p>To request an interview opportunity:<br/><b>Media </b><br/>Amy Bonwick<br/>647-515-3748<br/>amy@pomppr.com</p>\n<p>Ranjit Dhatt<br/>647-890-2445<br/>ranjit@pomppr.com</p>\n<p><b>Investors </b><br/>Raphael Gross<br/>203-682-8253<br/>Raphael.Gross@icrinc.com</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray® Exports First Shipment of Medical Cannabis to Spain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray® Exports First Shipment of Medical Cannabis to Spain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-04 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tilray-exports-first-shipment-medical-110000457.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis\nTilray medical cannabis will now be available in 17 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tilray-exports-first-shipment-medical-110000457.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://finance.yahoo.com/news/tilray-exports-first-shipment-medical-110000457.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2108711273","content_text":"Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis\nTilray medical cannabis will now be available in 17 countries around the world\nTilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech (\"Worldpharma\"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (\"Tilray Portugal\"), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17th country to receive Tilray medical cannabis worldwide.\nThe Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain. With Tilray's pharmaceutical-grade cannabis, Worldpharma will develop medical cannabis products for clinical trials in Spanish Hospitals for diseases such as Alzheimer's, Parkinson’s disease, and skin inflammation.\nBrendan Kennedy, Tilray’s Chief Executive Officer, said, \"We’re incredibly honored to be the first cannabis company to be approved and to ship medical cannabis into Spain. As we continue to work with regulators around the world, we are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.\"\nJuan Jose Garcia Miquel, Founder of World Pharma Biotech, said, \"We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP certified products that meet the highest of E.U. and Spanish Pharmacology Standards. We intend to work with the companies with the highest quality pharmaceutical standards to give doctors and patients total confidence. It's been impossible to reach this level of quality from other cannabis authorized companies in Spain.\"\nSascha Mielcarek, Tilray’s General Manager for Europe, said, \"We are very pleased to partner with Worldpharma. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need, paving the way for future medical cannabis standards of care.\"\nTilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.\nTilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.\nAbout Tilray®\nTilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.\nAbout WorldPharma Biotech\nWorld Pharma Biotech was founded in 2014 in Valencia, Spain, focused on vegetal ingredients for nutraceuticals, cosmetics, and pharmaceutical industries. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and Start-up companies from Valencia University. The extraction and purification lab's primary focus is the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.\nForward-Looking Statements\nThis press release contains \"forward-looking statements\" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and \"forward-looking information\" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, \"may\", \"would\", \"could\", \"will\", \"likely\", \"expect\", \"anticipate\", \"believe, \"intend\", \"plan\", \"forecast\", \"project\", \"estimate\", \"outlook\" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading \"Risk Factors\" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210204005187/en/\nContacts\nFor further information: Tilray Global:Berrin Nooratanews@tilray.com\nTo request an interview opportunity:Media Amy Bonwick647-515-3748amy@pomppr.com\nRanjit Dhatt647-890-2445ranjit@pomppr.com\nInvestors Raphael Gross203-682-8253Raphael.Gross@icrinc.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":332500134,"gmtCreate":1610423837028,"gmtModify":1703744201197,"author":{"id":"3560331351209354","authorId":"3560331351209354","name":"任长老","avatar":"https://static.tigerbbs.com/b5b555697d10a84da2515eebe013f79a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560331351209354","authorIdStr":"3560331351209354"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TLRY\">$Tilray Inc.(TLRY)$</a>如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点","listText":"<a href=\"https://laohu8.com/S/TLRY\">$Tilray Inc.(TLRY)$</a>如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点","text":"$Tilray Inc.(TLRY)$如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/332500134","isVote":1,"tweetType":1,"viewCount":4034,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3548126242847346","authorId":"3548126242847346","name":"hsuan","avatar":"https://static.tigerbbs.com/962664f269c8a1ec44a3c7227b45b174","crmLevel":5,"crmLevelSwitch":0,"idStr":"3548126242847346","authorIdStr":"3548126242847346"},"content":"如果开始投票，简单多数也就是51票就够了。但问题是要投票得先结束辩论，要结束辩论需要60票支持才行。所以绕了一圈，还是相当于要60票才行。但也有办法能绕过60票的限制，就是所谓的“核选项”，核选项大概就是修改规则，让特定的议案可以以简单多数的方式通过。核选项顾名思义，不到万不得已是不能使用的，到目前为止，两党总共也只动用了两次核选项，所以预计民主党为了大麻动用核选项的可能性不大。","text":"如果开始投票，简单多数也就是51票就够了。但问题是要投票得先结束辩论，要结束辩论需要60票支持才行。所以绕了一圈，还是相当于要60票才行。但也有办法能绕过60票的限制，就是所谓的“核选项”，核选项大概就是修改规则，让特定的议案可以以简单多数的方式通过。核选项顾名思义，不到万不得已是不能使用的，到目前为止，两党总共也只动用了两次核选项，所以预计民主党为了大麻动用核选项的可能性不大。","html":"如果开始投票，简单多数也就是51票就够了。但问题是要投票得先结束辩论，要结束辩论需要60票支持才行。所以绕了一圈，还是相当于要60票才行。但也有办法能绕过60票的限制，就是所谓的“核选项”，核选项大概就是修改规则，让特定的议案可以以简单多数的方式通过。核选项顾名思义，不到万不得已是不能使用的，到目前为止，两党总共也只动用了两次核选项，所以预计民主党为了大麻动用核选项的可能性不大。"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":332500134,"gmtCreate":1610423837028,"gmtModify":1703744201197,"author":{"id":"3560331351209354","authorId":"3560331351209354","name":"任长老","avatar":"https://static.tigerbbs.com/b5b555697d10a84da2515eebe013f79a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560331351209354","authorIdStr":"3560331351209354"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TLRY\">$Tilray Inc.(TLRY)$</a>如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点","listText":"<a href=\"https://laohu8.com/S/TLRY\">$Tilray Inc.(TLRY)$</a>如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点","text":"$Tilray Inc.(TLRY)$如果议案拿到参议院，需要多少票可以通过？之前看过一篇报道，需要60%的投票才能通过，那岂不是大麻合法化的难度依然很高？希望哪位明白的大神指点","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/332500134","isVote":1,"tweetType":1,"viewCount":4034,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3548126242847346","authorId":"3548126242847346","name":"hsuan","avatar":"https://static.tigerbbs.com/962664f269c8a1ec44a3c7227b45b174","crmLevel":5,"crmLevelSwitch":0,"idStr":"3548126242847346","authorIdStr":"3548126242847346"},"content":"如果开始投票，简单多数也就是51票就够了。但问题是要投票得先结束辩论，要结束辩论需要60票支持才行。所以绕了一圈，还是相当于要60票才行。但也有办法能绕过60票的限制，就是所谓的“核选项”，核选项大概就是修改规则，让特定的议案可以以简单多数的方式通过。核选项顾名思义，不到万不得已是不能使用的，到目前为止，两党总共也只动用了两次核选项，所以预计民主党为了大麻动用核选项的可能性不大。","text":"如果开始投票，简单多数也就是51票就够了。但问题是要投票得先结束辩论，要结束辩论需要60票支持才行。所以绕了一圈，还是相当于要60票才行。但也有办法能绕过60票的限制，就是所谓的“核选项”，核选项大概就是修改规则，让特定的议案可以以简单多数的方式通过。核选项顾名思义，不到万不得已是不能使用的，到目前为止，两党总共也只动用了两次核选项，所以预计民主党为了大麻动用核选项的可能性不大。","html":"如果开始投票，简单多数也就是51票就够了。但问题是要投票得先结束辩论，要结束辩论需要60票支持才行。所以绕了一圈，还是相当于要60票才行。但也有办法能绕过60票的限制，就是所谓的“核选项”，核选项大概就是修改规则，让特定的议案可以以简单多数的方式通过。核选项顾名思义，不到万不得已是不能使用的，到目前为止，两党总共也只动用了两次核选项，所以预计民主党为了大麻动用核选项的可能性不大。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":317626583,"gmtCreate":1612446954342,"gmtModify":1703762000043,"author":{"id":"3560331351209354","authorId":"3560331351209354","name":"任长老","avatar":"https://static.tigerbbs.com/b5b555697d10a84da2515eebe013f79a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560331351209354","authorIdStr":"3560331351209354"},"themes":[],"htmlText":"绝对的龙头","listText":"绝对的龙头","text":"绝对的龙头","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/317626583","repostId":"2108711273","repostType":2,"repost":{"id":"2108711273","pubTimestamp":1612436400,"share":"https://www.laohu8.com/m/news/2108711273?lang=&edition=full","pubTime":"2021-02-04 19:00","market":"us","language":"en","title":"Tilray® Exports First Shipment of Medical Cannabis to Spain","url":"https://stock-news.laohu8.com/highlight/detail?id=2108711273","media":"Business Wire","summary":"Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain wi","content":"<html><body><p><b><i>Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis</i></b></p>\n<p><b><i>Tilray medical cannabis will now be available in 17 countries around the world</i></b></p>\n<p>Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech (\"Worldpharma\"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (\"Tilray Portugal\"), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17<sup>th</sup> country to receive Tilray medical cannabis worldwide.</p>\n<p>The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain. With Tilray's pharmaceutical-grade cannabis, Worldpharma will develop medical cannabis products for clinical trials in Spanish Hospitals for diseases such as Alzheimer's, Parkinson’s disease, and skin inflammation.</p>\n<p>Brendan Kennedy, Tilray’s Chief Executive Officer, said, \"We’re incredibly honored to be the first cannabis company to be approved and to ship medical cannabis into Spain. As we continue to work with regulators around the world, we are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.\"</p>\n<p>Juan Jose Garcia Miquel, Founder of World Pharma Biotech, said, \"We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP certified products that meet the highest of E.U. and Spanish Pharmacology Standards. We intend to work with the companies with the highest quality pharmaceutical standards to give doctors and patients total confidence. It's been impossible to reach this level of quality from other cannabis authorized companies in Spain.\"</p>\n<p>Sascha Mielcarek, Tilray’s General Manager for Europe, said, \"We are very pleased to partner with Worldpharma. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need, paving the way for future medical cannabis standards of care.\"</p>\n<p>Tilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.</p>\n<p>Tilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.</p>\n<p><b>About Tilray®</b></p>\n<p>Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.</p>\n<p><b>About WorldPharma Biotech</b></p>\n<p>World Pharma Biotech was founded in 2014 in Valencia, Spain, focused on vegetal ingredients for nutraceuticals, cosmetics, and pharmaceutical industries. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and Start-up companies from Valencia University. The extraction and purification lab's primary focus is the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains \"forward-looking statements\" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and \"forward-looking information\" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, \"may\", \"would\", \"could\", \"will\", \"likely\", \"expect\", \"anticipate\", \"believe, \"intend\", \"plan\", \"forecast\", \"project\", \"estimate\", \"outlook\" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading \"Risk Factors\" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210204005187/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>For further information: </b><br/>Tilray Global:<br/>Berrin Noorata<br/>news@tilray.com</p>\n<p>To request an interview opportunity:<br/><b>Media </b><br/>Amy Bonwick<br/>647-515-3748<br/>amy@pomppr.com</p>\n<p>Ranjit Dhatt<br/>647-890-2445<br/>ranjit@pomppr.com</p>\n<p><b>Investors </b><br/>Raphael Gross<br/>203-682-8253<br/>Raphael.Gross@icrinc.com</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray® Exports First Shipment of Medical Cannabis to Spain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray® Exports First Shipment of Medical Cannabis to Spain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-04 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tilray-exports-first-shipment-medical-110000457.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis\nTilray medical cannabis will now be available in 17 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tilray-exports-first-shipment-medical-110000457.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://finance.yahoo.com/news/tilray-exports-first-shipment-medical-110000457.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2108711273","content_text":"Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis\nTilray medical cannabis will now be available in 17 countries around the world\nTilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech (\"Worldpharma\"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (\"Tilray Portugal\"), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17th country to receive Tilray medical cannabis worldwide.\nThe Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain. With Tilray's pharmaceutical-grade cannabis, Worldpharma will develop medical cannabis products for clinical trials in Spanish Hospitals for diseases such as Alzheimer's, Parkinson’s disease, and skin inflammation.\nBrendan Kennedy, Tilray’s Chief Executive Officer, said, \"We’re incredibly honored to be the first cannabis company to be approved and to ship medical cannabis into Spain. As we continue to work with regulators around the world, we are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.\"\nJuan Jose Garcia Miquel, Founder of World Pharma Biotech, said, \"We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP certified products that meet the highest of E.U. and Spanish Pharmacology Standards. We intend to work with the companies with the highest quality pharmaceutical standards to give doctors and patients total confidence. It's been impossible to reach this level of quality from other cannabis authorized companies in Spain.\"\nSascha Mielcarek, Tilray’s General Manager for Europe, said, \"We are very pleased to partner with Worldpharma. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need, paving the way for future medical cannabis standards of care.\"\nTilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.\nTilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.\nAbout Tilray®\nTilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.\nAbout WorldPharma Biotech\nWorld Pharma Biotech was founded in 2014 in Valencia, Spain, focused on vegetal ingredients for nutraceuticals, cosmetics, and pharmaceutical industries. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and Start-up companies from Valencia University. The extraction and purification lab's primary focus is the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.\nForward-Looking Statements\nThis press release contains \"forward-looking statements\" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and \"forward-looking information\" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, \"may\", \"would\", \"could\", \"will\", \"likely\", \"expect\", \"anticipate\", \"believe, \"intend\", \"plan\", \"forecast\", \"project\", \"estimate\", \"outlook\" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading \"Risk Factors\" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210204005187/en/\nContacts\nFor further information: Tilray Global:Berrin Nooratanews@tilray.com\nTo request an interview opportunity:Media Amy Bonwick647-515-3748amy@pomppr.com\nRanjit Dhatt647-890-2445ranjit@pomppr.com\nInvestors Raphael Gross203-682-8253Raphael.Gross@icrinc.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}